title: [Primary safety analysis of trastuzumab after adjuvant chemotherapy in 30 Chinese Her2-positive early breast cancer patients].
abstract: OBJECTIVE
  It has been proved that trastuzumab has clinical activity in early and advanced breast cancer with Her2-overexpression. This study was to analyze the safety of trastuzumab after adjuvant chemotherapy in 30 Chinese Her2-positive early breast cancer patients.
  
  
  METHODS
  Trastuzumab was administrated after adjuvant chemotherapy every 21 days. The initial dose was 8 mg/kg, and the subsequent dose was 6 mg/kg, for four to 35 cycles (medium 18 cycles). The side effects of these patients, especially cardiotoxicity, were analyzed.
  
  
  RESULTS
  Thirty patients with Her2-positive early breast cancer were entered into the study. The average treatment period was one year (range nine weeks to two years). Two patients had shivering and fever during the first infusion with trastuzumab. Left ventricular ejection fraction (LVEF) level dropped in 18 cases after treatment with trastuzumab, half of which decreased more then 10%û however, no cardiac failure was observed.
  
  
  CONCLUSIONS
  The post-surgical treatment of trastuzumab in Chinese patients with Her2-positive early breast cancer shows a satisfactory safety profile. However, the potential cardiotoxicity of trastuzumab should be carefully monitored during therapy.
authors.affiliation: State Key laboratory of Oncology in South China, Guangzhou, Guandong, 510060, PR China.
authors.forename: Ning-Ning
authors.initials: NN
authors.lastname: Zhou
authors.forename: Xiao-Yu
authors.initials: XY
authors.lastname: Teng
authors.forename: Dong-Geng
authors.initials: DG
authors.lastname: Liu
authors.forename: Ran
authors.initials: R
authors.lastname: Xu
authors.forename: Zhong-Zhen
authors.initials: ZZ
authors.lastname: Guan
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000097:blood / Q000628:therapy*; D018270:Carcinoma, Ductal, Breast / Q000097:blood / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D005260:Female; D005334:Fever / Q000139:chemically induced; D006334:Heart Function Tests; D006801:Humans; D008408:Mastectomy; D008875:Middle Aged; D011184:Postoperative Period; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000097:blood; D012189:Retrospective Studies; D012768:Shivering; D013318:Stroke Volume; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab